BHV Partners has opened a seed funding round of €2.5 million to accelerate its growth as a venture builder specialising in creating start-ups in thehealth sector. The round is aimed at family offices and companies with corporate venture funds, as well as existing partners.

Creatio, partner of CataloniaBio & Health Tech and production and validation centre for advanced therapies of the University of Barcelona, through the Bosch i Gimpera Foundation, has acquired UTOX, the experimental toxicology platform of the Barcelona Science Park (PCB). The aim of this acquisition is for UTOX to be integrated into the Creatio technology development centre, a leader in advanced therapies and a member of the TECNIO network. 

OneChain Immunotherapeutics, spin-off from the Josep Carreras Leukaemia Research Institute and Dr. Pablo Menéndez, as well as a portfolio company of OneChain, both partners of CataloniaBio & HealthTech, announce the closing of a pre-series financing round where they have counted with the participation of Invivo Capital, also partners. 

Ysios Capital, a leading venture capital firm in the biotech sector and member of CataloniaBio & HealthTech, announced today its participation in the financing round of the Dutch company Tagworks Pharmaceuticals for a total amount of 64 million dollars (over 58 million euros).

A total of 51 companies in 17 countries have been selected by the European Innovation Council Accelerator, in a competitive process involving 551 candidates. MiMARK Diagnostics and the Madrid-based company, Oils4Cure have been the only Spanish companies to be chosen.

GENESIS Tech Transfer Boost, an investment vehicle created in 2022 and managed by the consultancy firm GENESIS Biomed, has made its first investment for a ticket of €25,000 in the biotech company Spinally Medical. The vehicle formed by GENESIS Biomed, FI Group and Crowd4Ventures for a total of €1M for 4 years, aims to detect and invest in early-stage projects in the biomedical sector from the health and academic environments.

Biotech company SpliceBio, members of CataloniaBio & HealthTech, has announced the appointment of David Favre, D.V.M., Ph.D., as Chief Development Officer (CDO). Dr. Favre brings extensive experience in gene therapy, immunology and drug development. 

Nuage Therapeutics (“Nuage”), companyia biotecnològica que desenvolupa un motor de descobriment de nous fàrmacs moduladors de proteïnes intrínsecament desordenades (IDPs), anuncia avui el tancament d’un finançament inicial de 12 milions d’euros per donar suport al desenvolupament del seu programa principal i validar la seva plataforma pionera de descobriment de fàrmacs

Medichem, partners of CataloniaBio & HealthTech and supplier to the pharmaceutical industry, is expanding its production in Spain and opening new markets in Brazil. With an investment of 16.5 million euros, the company will establish its fourth production floor in the Technology Park of Asturias. It has also obtained certification from the Brazilian Health Regulatory Agency (Anvisa) to sell active ingredients and medicines on the market. 

Mitelos, partner of CataloniaBio & HealthTech, is the leading manufacturer of medical devices. Today it announces the renewal of the ISO 13485:2016 certification. This certification demonstrates Mitelos' commitment to providing high quality medical devices that meet the rigorous standards set by the International Organization for Standardization (ISO). 

The Hospital Clínic Barcelona has successfully performed the first surgeries with Bitrack, the surgical robot created by the Catalan company, Rob Surgical. The first surgeries were three radical nephrectomies and all three surgeries were performed satisfactorily, and, after a 30-day follow-up, no adverse events were observed as a result of the use of the Bitrack system.

Abzu, the Danish / Spanish startup that has introduced new methods and technology to drive discoveries in life science research, wins the Best HealthTech at the 2023 Nordic Startup Awards. The Best HealthTech award recognizes a startup with innovative and impactful technology solutions with a quantifiable positive impact on health and healthcare outcomes.

The funding raised by the companies that form part of the PCB Community, in transactions identified in 2022, reached €142M, an absolute record, of which €85M (58%) came from private capital. The Barcelona Science Park (PCB) comprises more than 125 entities, including the CataloniaBio & HealthTech offices and a large number of partners.

Miquel Vila Perelló (Barcelona, 1977) has a PhD in Chemistry (UB) and is a co-founder of SpliceBio, a biotech company that develops gene therapies for rare disorders for which there is no cure yet. The Bioèxit 2022 award is in recognition of the Series A €50M finance round, led jointly by UCB Ventures (Belgium) and Ysios Capital, with the participation of a powerful international syndicate. A spinoff of Princeton University, it was set up and established in Barcelona in 2012. 

It is a path that poses a special challenge for the limited resources available to biotech start-ups. For this reason, CataloniaBio & HealthTech brought together five experts from member companies, with knowledge and experience in different phases of the pharmaceutical development process, to share lessons learned in the usual Lessons Learned format. The session took place at the Barcelona Science Park.

Ship2B Ventures, a member of CataloniaBio & HealthTech, is launching a €30 million fund to invest in European companies in the field of paediatrics. The new fund is called Montana Impact Fund and plans to invest in between 16 and 18 companies in the early stages of research. 

MiMARK Diagnostics, member of CataloniaBio & HealthTech , specialises in the development of innovative solutions for gynaecological diagnostics. The Vall d’Hebron Research Institute (VHRI) spin-off has raised €1m to accelerate the development of its in vitro diagnostic test for endometrial cancer WomEC and initiate the development plan for its diagnostic test for endometriosis.

Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, announced the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD).

Clinicas Mi and HumanITcare have signed a collaboration agreement to accompany cancer patients throughout their treatment, from any location, 24 hours a day, 365 days a year.

Global biopharmaceutical company Almirall, a member of CataloniaBio &HealthTech, has entered into a research collaboration with the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence. The partnership aims to develop and characterize novel preclinical models that will help identify new treatments for non-melanoma skin cancer (NMSC).